Born 1961. Chairman of the Board since 2024
Education & experience
A Master’s degree in Chemical Engineering from the Swedish Royal Institute of Technology KTH in Stockholm. Otto Skolling has more than 30 years of experience in product development, business development and project management in the pharmaceutical and medical technology industry and has previously held management positions at, among others, Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn. Otto has also been the chair of the Board of Volusense AS and a board member of Asarina Pharma AB, Bactaviva AB, Nanexa AB and Athera Biotechnologies AB.
Other current assignments
Otto Skolling is currently Chief Business Officer at Asarina Pharma AB and a Board member of Isles of Wines AB, Respinor AB (publ), Lipidor AB and Pharmor AB. He is also business development responsible for Nanexa AB and Dilafor AB.
Shares: 0
Warrants: 350,000 of series 2023/2025:2
Born 1974. Board Member since November 2014.
Education & experience
BSc from the London School of Economics. Henrik has many years of experience in private equity and has worked at Axcel Management AB from 2008 to 2013 and at Triton Advisers (Sweden) AB from 2002 to 2007. Today, Henrik works as a private investor in a number of other companies.
Other current assignments
Member of MYoroface AB, SnowSail Invest AB, Rammer Holding AB, RRMC AB, RRM Nordic Financial Services Acquistion AB, Domeject AB, chair of the Board of Homekey AB and RRM Sponsor AB and alternate member of Gunnbjorn AB.
Shares: 13,300
Warrants: 350,000 of series 2023/2025:2
Born 1955. Board member since June 2014.
Education & experience
Chemical Engineering degree course followed by a tertiary education in economics. Tommy was CEO of Atos Medical from 1998 to 2014 and a member of its Board of Directors from 2014 to 2016. Prior to this he also worked with sales and marketing at Atos Medical, where he started in 1990. Before Tommy started working at Atos Medical, he worked with sales and marketing at Medscand AB and Janssen Pharma AB. Tommy has previously been a Board member of Carponovum AB, M-V Arterica AB, and Cross Technology Solutions AB.
Other current assignments
Tommy currently has a number of other Board assignments in the life sciences sector. Tommy is a member and chair of the Board of Directors of C LindheXtend Aktiebolag. Tommy is also a member of Avidicare Holding AB, Askis AB and Neola Medical AB.
Shares: (and through related parties) 100,999
Warrants: 225,000 of series 2023/2025:2
Born 1963. Board member since April 2017.
Education & experience
Medical BSc and Executive MBA from Uppsala University. Gunilla is currently the CEO of Uppsala Universitet Invest AB. She has held leading positions in the life science sector for more than 25 years. Most recently, Gunilla was CEO of Pharmanest AB, where she led development from concept phase to commercialization. Prior to that, Gunilla was Deputy CEO of Q-Med AB. Gunilla was also a member of Linnéa Capital I AB, Strike Pharma AB, Uppsala-Gruppen Utbildning & Organisation Aktiebolag, Addbio AB and CombiGene AB and an alternate Board member of Chaine AB.
Other current assignments
Gunilla is a member of IPF – Institutet för Personal- och Företagsutveckling Aktiebolag, Uppsala University Projekt Aktiebolag, Uppsala Innovation Centre AB, Lipidor AB, Uppsala Universitet Research Intellectual Property AB and SampleFacts AB, and she is an alternate Board member of Uppsala-Gruppen Utbildning & Organisation Aktiebolag.
Shares: 0
Warrants: 350,000 of series 2023/2025:2
Born 1979. Board member since October 2021.
Education & experience
MSc in Engineering Physics with an MSc from Uppsala University and an Executive MBA from Stockholm University. Caroline is a certified Board Member, Styrelseakademien. Caroline is currently Senior Sales Specialist Sustainability at the software technology company Stratsys, and has previously worked at Ericsson, among others, in various leading roles with a focus on sales and marketing. Caroline has previously been a Board Member of Viddget Holding AB. She also has a number of different directorships and advisory board roles, including at Stockholm University.
Other current assignments
Caroline is an alternate Board member of Just Management Euroclear Sweden AB.
Shares: (and through related parties) 99,670
Warrants: 225,000 of series 2023/2025:2
Öhrlings PricewaterhouseCoopers with authorized public accountant Henrik Boman as principal auditor.
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.
Färögatan 33
SE-164 51 Kista
Sweden
For visits: floor B31
Delivery: Hanstavägen 31, 164 53 Kista
